Late onset renal failure from angiotensin blockade (LORFFAB) and the syndrome of rapid onset end-stage renal disease (SORO-ESRD) revisited – Two case reports from Mayo Clinic Health System, Northwestern Wisconsin, USA; a review paper

Macaulay Amechi Chukwukadibia Onuigbo1,2*, Eileen Samuel2, Nneoma Agbasi3

1Mayo Clinic College of Medicine, Rochester, MN, USA
2Department of Nephrology, Mayo Clinic Health System, Eau Claire, WI, USA
3North East London NHS Foundation Trust, UK

*Corresponding author: Macaulay Amechi Chukwukadibia Onuigbo, Email: onuigbo.macaulay@mayo.edu

Article History:
Received: 9 August 2017
Accepted: 20 November 2017
Published online: 2 January 2018

ARTICLE INFO

Article Type: Review

Article History:
Received: 9 August 2017
Accepted: 20 November 2017
Published online: 2 January 2018

Keywords:
Acute kidney injury, Angiotensin blockade, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Chronic kidney disease, Late onset renal failure from angiotensin blockade

ABSTRACT

In 2005, we described for the first time, the syndrome of late onset renal failure from angiotensin blockade (LORFFAB). This is accelerated loss of kidney function in patients on a priori stable doses of an angiotensin converting enzyme inhibitor and/or an angiotensin receptor blocker (ARB), for more than 3 months, with this acute kidney injury (AKI) occurring in the absence of any identifiable known precipitating factors. Moreover, in 2010, we described the syndrome of rapid onset end-stage renal disease (SORO-ESRD). This is acute yet irreversible renal failure following medical illness or surgical procedures, again sometimes in association with concurrent angiotensin blockade. In this article, we describe two representative case reports, one case for LORFFAB and another case for SORO-ESRD and subsequently discuss the implications of LORFFAB and SORO-ESRD in current nephrology practice paradigms. Whereas we support the consensus that angiotensin blockade, for now, remains the mainstay of renoprotection, we however must draw attention to the potential for nephrotoxicity from angiotensin blockade under certain clinical scenarios including the ones described here and more. The association of LORFFAB and SORO-ESRD demands further investigation.

Implication for health policy/practice/research/medical education:
In 2005, we had described for the first time, the syndrome of late onset renal failure from angiotensin blockade (LORFFAB), represented by the observed accelerated loss of kidney function in patients on a priori stable doses of an angiotensin converting enzyme inhibitor and/or an angiotensin receptor blocker, for more than three months, with this acute kidney injury (AKI) occurring despite the absence of any identifiable known precipitating factors. Moreover, in 2010, we had described the syndrome of rapid onset end-stage renal disease (SORO-ESRD), represented by acute yet irreversible renal failure following medical illness or surgical procedures, again sometimes in association with concurrent angiotensin blockade. In this article, we describe two representative case reports, one each of both syndromes, and discuss the implications of LORFFAB and SORO-ESRD in current nephrology practice paradigms.

Please cite this paper as: Onuigbo M, Samuel E, Agbasi N. Late onset renal failure from angiotensin blockade (LORFFAB) and the syndrome of rapid onset end-stage renal disease (SORO-ESRD) revisited – Two case reports from Mayo Clinic Health System, Northwestern Wisconsin, USA; a review paper. J Renal Inj Prev. 2018;7(2):58-63. DOI: 10.15171/jrip.2018.15.

Introduction
In 2005, from the Renal Unit of Mayo Clinic Health System, in Northwestern Wisconsin, we had described for the first time, the syndrome of late onset renal failure from angiotensin blockade (LORFFAB) (1). The classic diagnosis of this syndrome of LORFFAB was predicated on a patient satisfying the following criteria (1–6).
1. The presence of ≥25% increase in baseline serum
creatinine, while on concomitant angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) therapy.

2. The dose(s) of angiotensin inhibition must have been the same for at least three months prior to presentation.

3. All the previously described so-called traditional precipitating risk factors for renal failure associated with angiotensin inhibition including hypotension, nonsteroidal anti-inflammatory drugs (NSAIDs) use, dehydration, iodinated contrast exposure and heart failure exacerbation must be absent.

4. The patient must demonstrate angiographic evidence of normal renal arteries.

Furthermore, in 2010, we had described the syndrome of rapid onset end-stage renal disease (SORO-ESRD), represented by acute yet irreversible renal failure, requiring the institution of renal replacement therapy (RRT), following medical events or surgical procedures, again often in association with concurrent angiotensin blockade (7). Our working definition of SORO-ESRD is any patient with an a priori stable estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73 m², on or before the 90th day preceding initiation of first RRT for renal failure, who develops renal failure from an acute kidney injury (AKI) event and who thereafter had remained permanently on RRT for over 90 days and beyond without renal recovery (7-10). Quite often, the interval between the precipitating AKI event and the need for RRT is less than 2 weeks, and commonly is only in days following cardiothoracic procedures (7-10).

Following our reports on the syndrome of LORFFAB and having raised concerns regarding the unrecognized potential nephrotoxicity associated with angiotensin blockade, similar experiences have been observed in a few other centers around the world, including the work of El Nahas and his group from the Sheffield Kidney Institute, Sheffield, in the United Kingdom, implicating angiotensin blockade in the causation of clinically significant and sometimes unrecognized renal failure (11-13).

In this article, we describe two representative case reports, one each of both syndromes, and discuss the implications of LORFFAB and SORO-ESRD in current nephrology practice paradigms.

**Case I - LORFFAB**

In April 2016, our nephrology outpatient service was consulted regarding an active 74-year old hypertensive Caucasian male patient, an ex-smoker, for worsening renal failure. Other past medical history included coronary artery stents with angioplasties in 1986 and 1997, impaired glucose tolerance, gout, obesity and abdominal aortic aneurysm repair in 2002, prior history of recovered acute renal failure secondary to NSAIDs, and stage III chronic kidney disease (CKD) with prior baseline serum creatinine of about 1.5 mg/dL in 2014 and 2015 – serum creatinine was 1.48 mg/dL in October 2014 and 1.45 mg/dL in October 2015. Outpatient medications in April 2016 included lisinopril 20 mg daily, baby aspirin 81 mg daily, atenolol 50 mg two times daily, atorvastatin 40 mg daily, omeprazole 20 mg daily, as needed aceraminophen and sublingual nitroglycerin. Records show that the lisinopril was started in September 2015.

He had seen his internist for a scheduled annual examination and was otherwise asymptomatic. Heart rate 68, blood pressure 112/72 mm Hg, weight is 89.8 kg. No edema was evident, and physical examination overall was unremarkable. Laboratory testing revealed significantly elevated serum creatinine at 3.18 mg/dL, with associated hyperkalemia of 5.8 mmol/L (Figures 1 and 2). The diagnosis was suspected lisinopril nephrotoxicity and he was sent to the emergency room where he received 500 cc intravenous bolus of normal saline, followed by a single intravenous dose of furosemide and lisinopril was promptly discontinued. He was then followed up in the Nephrology office the following week.

Just the next day, serum creatinine had decreased to 2.48 mg/dL, and was down to 2.21 mg/dL twelve days later (Figure 3). It was 1.50 mg/dL about three months later and has remained stable since then. Serum potassium similarly had normalized twelve days later. The most recent serum creatinine from April 2017 is 1.53 mg/dL (Figure 4).

**Figure 1.** Serum creatinine trajectory, September 2014 through April 2016 showing accelerated loss of kidney function with a higher serum creatinine of 3.18 mg/dL during an annual review in April, 2016.

**Figure 2.** Serum potassium trajectory, September 2014 through April 2016 showing hyperkalemia of 5.8 mmol/L associated with acute kidney injury during an annual review in April, 2016.
Currently in April, 2017, he continues to maintain a stable serum creatinine of 1.53 mg/dL (eGFR = 45 mL/min/1.73 m² BSA), nearly a year later, and his current antihypertensive agents are amlodipine 5 mg daily, metoprolol tartrate 37.5 mg daily and tamsulosin 0.4 mg daily.

Case II – SORO-ESRD

In late February 2012, a 73-year old morbidly obese diabetic hypertensive Caucasian male patient, with stable stage III CKD, baseline serum creatinine ranging from 1.5-1.9 mg/dL (2005-2012) was evaluated for one week's history of worsening exertional dyspnea (Figure 5). He was on amlodipine 10 mg once daily, atenolol-chlorthalidone 100/25, one tablet daily, atorvastatin 80 mg daily, insulin isophane N 28 units daily before breakfast and 18 units at bedtime, with regular insulin, 9 units in the morning and 7 units at 4 PM. for glucose levels greater than 100 mg/dL, lisinopril 40 mg daily and multivitamin with minerals, one tablet daily.

Blood pressure control in February 2012 was adequate, temperature 36.6°C, pulse was 57 per minute, respiratory rate 16 per minute, blood pressure 147/76 mm Hg, saturating at 93% on 3 L/min nasal cannula oxygen. HgA1c was 7%, serum creatinine was 1.72 mg/dL (eGFR of 39 mL/min/1.73 m² BSA). An echocardiogram revealed moderate left ventricular hypertrophy, elevated right atrial filling pressure (>15 mm Hg), mild pulmonary hypertension (PASP 40-49 mm Hg) and critical/severe aortic stenosis. Left ventricular ejection fraction was 50% without any identifiable wall motion abnormalities. He underwent coronary angiography on 2-28-12 and there was no obstructive coronary artery disease.

On March 2, 2012, the patient underwent minimally invasive aortic valve replacement (AVR) with a 25 mm St. Jude Epic Stented Tissue Valve via cardiopulmonary bypass (CPB) – Bypass time was 150 minutes, Cross-Clamp time was 101 minutes and total operating room time under anesthesia was 7 hours (745 AM–1445 PM). By the end of the first post-operative day, the patient required the initiation of 24-hour continuous veno-venous hemodialysis (CVVHD) with ultrafiltration for worsening AKI (Figure 6), oligo-anuria and progressively increasing volume overload.

Emergent hemodialysis was started the very next day following the surgery due to rising creatinine (Figure 6), oligo-anuria and worsening volume overload. His hemodialysis regimen was 24 hours nonstop CVVHD with slow ultrafiltration for five days, and then was switched to shorter 4-6 hours daily hemodialysis treatments and by the second week was de-escalated to three times weekly hemodialysis. He has since remained on in-center outpatient three times a week a week hemodialysis at the Mayo Clinic Dialysis System Unit in Eau Claire, WI, USA for over 5 years. His current serum creatinine as at May 5, 2017 is 8.66 mg/dL and he remains anuric (Figure 7).

Discussion

The first case presented above demonstrated the potential for angiotensin blockade to cause nephrotoxicity, consistent with the diagnosis of LORFFAB. Since our first report of the syndrome of LORFFAB in 2005, over the last ten or more years, we have variously described the features of this syndrome in various journal publications, book chapters and editorial pieces as well as in professional academic intellectual forums.
and presentations (1-6). It was indeed our work at the Mayo Clinic Health System in Northwestern Wisconsin that spurred the work of El Nahas and his group from the Sheffield Kidney Institute, Sheffield in the United Kingdom who concluded in 2010 that discontinuation of ACEI/ARB had undoubtedly delayed the onset of RRT in the majority of those studied and that this observation might justify a rethink of our approach to the inhibition of the renin–angiotensin–aldosterone system (RAAS) in patients with advanced CKD who are nearing the start of RRT (11,12). Some other investigators around the world have shown similar reports raising concerns about the potential nephrotoxicity of angiotensin blockade especially in the elderly (>65-year old) with more advanced CKD (13-15). As a result of these legitimate concerns, we now have a randomized controlled trial to determine whether the pre-emptive withdrawal of ACEI/ARB in patients with advanced CKD would result in improved cardiorenal outcomes - the ongoing STOP ACEi Trial (16,17).

The second case report presented above demonstrated the syndrome of rapid onset ESRD, or SORO-ESRD, that is to say, acute yet irreversible renal failure requiring permanent RRT including kidney transplantation where applicable (7-10). Several other large studies of the trajectories of renal failure to ESRD have confirmed our observations (18-20). In the more recent nephrology literature, 2011-2012, we have further identified three corroborating new reports that have further substantiated our recent descriptions of the phenomenon of SORO-ESRD (18-20). These three reports have each additionally demonstrated that a significant proportion of the incident adult ESRD population in both the United States and Canada, respectively, satisfy the diagnostic criteria for our newly described syndrome of rapid onset end stage renal disease (18-20).

**Conclusion**

**LORFFAB and SORO-ESRD**

In conclusion, we acknowledge and support the consensus that angiotensin blockade, for now, remains the mainstay of renoprotection in general nephrology care. We however must draw attention to the potential for nephrotoxicity from angiotensin blockade in several clinical scenarios including the ones described here and more. The association of LORFFAB and SORO-ESRD demands further investigation. In our small 100-patient experience in northwestern Wisconsin, we were able to demonstrate an association of angiotensin blockade with SORO-ESRD (7-10). A just published report from Saudi Arabia revealed an association of continued angiotensin blockade with hospital-acquired AKI (15). Besides, we had demonstrated in a 13-year retrospective analysis of 1461 ESRD patient managed at Mayo Clinic, Rochester, 2001-2013, an incidence rate of SORO-ESRD of 10% but we were not able to show any association between SORO-ESRD and concurrent angiotensin blockade (21). Finally, we would call for caution in the use of angiotensin blockade in older (>65-year old) patients with advanced CKD. Serum creatinine must be monitored, closely and indefinitely. Notably, a new report from the United Kingdom showed that 10% of patients on ACEI/ARB had neither baseline nor follow-up monitoring of creatinine within 12 months before and 2 months after initiation of an ACEI/ARB, 28% had monitoring only at baseline, 15% only at follow-up, and 47% both at baseline and follow-up (22). Providers need to adhere more to the guidelines for safe use of ACE inhibitors and angiotensin receptor blockers (23).

**POST-SCRIPT**

One recurring theme in this presentation is the demonstration that the superb utility and value of the close and meticulous monitoring of individual-patient serum creatinine trajectories in the real-time management of AKI in hospitalized patients cannot be over-emphasized (24-26). The conclusion from our recent investigation of this paradigm of nephrology care was that the analysis of serum creatinine trajectories, both in real time and retrospectively, indeed provides supplementary superior diagnostic and prognostic insights in the management of the general nephrology patient.
Authors’ contribution
MACO: Conception, design, acquisition of data, data analysis, interpretation of data, literature review, drafting the article and final approval of manuscript. ES: Acquisition of data, literature review and final approval of manuscript. NA: Critical revising for important intellectual content, design, and final approval of manuscript.

Conflicts of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors. The patients had given their informed consent regarding these case reports. This paper is a review article along with case discussion.

Funding/Support
None.

References


